Merck (MRK) Construction in Progress (2009 - 2025)
Merck's (MRK) quarterly Construction in Progress came in at $9.2 billion in Q4 2025, up 14.8% year-over-year from $8.0 billion in Q4 2024, and up 14.8% quarter-over-quarter from $8.0 billion in Q4 2024.
Analysis
Merck (MRK) Construction in Progress (2009 - 2025) Analysis & Trends
Merck (MRK) has reported Construction in Progress for 17 consecutive years, with $9.2 billion the latest figure, recorded in Q4 2025.
- On a quarterly basis, Construction in Progress rose 14.8% year-over-year to $9.2 billion in Q4 2025; TTM through Dec 2025 was $9.2 billion, a 14.8% increase from a year earlier, with the FY2025 full-year figure at $9.2 billion, up 14.8% from the prior year.
- Construction in Progress was $9.2 billion for Q4 2025 at Merck, up from $8.0 billion in the prior quarter.
- Over five years, Construction in Progress peaked at $9.2 billion in Q4 2022 and troughed at $8.0 billion in Q4 2024.
- A 5-year average of $8.6 billion and a median of $8.3 billion in 2021 frame the typical range for Construction in Progress.
- Across the five-year window, Construction in Progress increased 19.3% in 2021 and fell 10.06% in 2023, its largest moves.
- Over 5 years, Construction in Progress stood at $8.3 billion in 2021, then grew by 10.5% to $9.2 billion in 2022, then fell by 10.06% to $8.3 billion in 2023, then fell by 3.36% to $8.0 billion in 2024, then grew by 14.8% to $9.2 billion in 2025.
- The last three Construction in Progress figures came in at $9.2 billion (Q4 2025), $8.0 billion (Q4 2024), and $8.3 billion (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | - |
| 10 | Jazz Pharmaceuticals | 16.02 Bn | 14.40 Bn | 1.09 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 9.17 Bn |
| Dec 31, 2024 | 7.98 Bn |
| Dec 31, 2023 | 8.26 Bn |
| Dec 31, 2022 | 9.19 Bn |
| Dec 31, 2021 | 8.31 Bn |
| Dec 31, 2020 | 6.97 Bn |
| Dec 31, 2019 | 5.01 Bn |
| Dec 31, 2018 | 3.36 Bn |
| Dec 31, 2017 | 2.30 Bn |
| Dec 31, 2016 | 1.87 Bn |
| Dec 31, 2015 | 1.53 Bn |
| Dec 31, 2014 | 1.45 Bn |
| Dec 31, 2013 | 1.81 Bn |
| Dec 31, 2012 | 2.44 Bn |
| Dec 31, 2011 | 2.20 Bn |
| Dec 31, 2010 | 2.07 Bn |
| Dec 31, 2009 | 1.82 Bn |